Intellia Therapeutics, Inc. Profile Avatar - Palmy Investing

Intellia Therapeutics, Inc.

Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the …
Biotechnology
US, Cambridge [HQ]
Value per Employee (VpE) · Surveys · Talents

Employees Analysis

Value per Employee (VpE)

Intellia Therapeutics, Inc. can't present you any valid VpE charts.

Employee Surveys Sample Size: -

There is no qualitative & current survey we can present at the moment.

Talent Acquisition

Permanent Employees Green Cards
Latest 12 Months
Employees
n/A
Wage Range
Min.:$n/A
Avg.:$n/A
Max.:$n/A
High Demand:

Intellia Therapeutics, Inc. can't present the data

Other Demand
  • Not available for Intellia Therapeutics, Inc.
Temporary Employees H1Bs
Latest 12 Months
Employees
n/A
Wage Range
Min.:$n/A
Avg.:$n/A
Max.:$n/A
High Demand:

Intellia Therapeutics, Inc. can't present the data

Other Demand
  • Not available for Intellia Therapeutics, Inc.

geographical
binding & acquisition

U.S. · Company Locations
Worldwide · Talent Acquisition
End of NTLA's Analysis
CIK: 1652130 CUSIP: 45826J105 ISIN: US45826J1051 LEI: - UEI: -
Secondary Listings
NTLA has no secondary listings inside our databases.